Search
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Categories: Heterocyclic Compounds, 1-RingEpcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigationalContinued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). … B cells.
Categories: Bispecific CD20-directed CD3 T Cell EngagerProducts: Tepkinly 4 mg/0,8 ml Enjeksiyonluk Çözelti (1 adet), Tepkinly 48 mg Enjeksiyonluk Çözelti (1 adet)Ferrous fumarate
go.drugbank.com/drugs/DB14491ApprovedInvestigationalUsed in treatment of iron deficiency anemia.
Mixtures: WOMEN`S MULTIVITE WITH EVENING PRIMROSE OIL,ROYAL JELLY & KOREAN GINSENG, Se-Vate 21/7Synonyms: Iron(2+) fumarateAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[A224039, L15311, L15316] Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells. … [A224044, L20974] It is set to enter phase 3 clinical trials.
Lactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedIt is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3. … (From Stedman, 26th ed) Sodium lactate is the sodium salt of lactic acid, and has a mild saline taste.
Mixtures: LACTATED RINGER`S SOLUTION 500ML, (HARTMANN`S SOLUTION ) WITH 5% GLUCOSE IN 1000 ML PLASTIC CONTAINERSynonyms: 2-Hydroxypropanoic acid, 2-Hydroxypropionic acidOzenoxacin
go.drugbank.com/drugs/DB12924Approveds Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingThreonine
go.drugbank.com/drugs/DB00156ApprovedInvestigationalNutraceuticalAn essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
Mixtures: AMINOACIDI S BIOINDUSTRIA L.I.M., AMINOSTERIL N-HEPA 8%Synonyms: L-2-Amino-3-hydroxybutyric acid, L-α-amino-β-hydroxybutyric acidAzidocillin
go.drugbank.com/drugs/DB08795ExperimentalAzidocillin is a penicillin antibiotic similir to ampicillin.
Categories: Heterocyclic Compounds, 2-RingSynonyms: (2S,5R,6R)-6-{[(2R)-2-azido-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, D-(−)-(α-azidobenzyl)penicillinAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. … Alpelisib is marketed under the trade name Piqray and is available as oral tablets.
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index